HomeComparePBLAX vs MRK

PBLAX vs MRK: Dividend Comparison 2026

PBLAX yields 24.73% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PBLAX wins by $40.4K in total portfolio value
10 years
PBLAX
PBLAX
● Live price
24.73%
Share price
$33.66
Annual div
$8.32
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$97.2K
Annual income
$10,855.51
Full PBLAX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — PBLAX vs MRK

📍 PBLAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPBLAXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PBLAX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PBLAX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PBLAX
Annual income on $10K today (after 15% tax)
$2,102.22/yr
After 10yr DRIP, annual income (after tax)
$9,227.18/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, PBLAX beats the other by $898.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PBLAX + MRK for your $10,000?

PBLAX: 50%MRK: 50%
100% MRK50/50100% PBLAX
Portfolio after 10yr
$77.0K
Annual income
$10,326.83/yr
Blended yield
13.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

PBLAX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PBLAX buys
0
MRK buys
0
No recent congressional trades found for PBLAX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPBLAXMRK
Forward yield24.73%2.76%
Annual dividend / share$8.32$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$97.2K$56.8K
Annual income after 10y$10,855.51$9,798.13
Total dividends collected$61.2K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PBLAX vs MRK ($10,000, DRIP)

YearPBLAX PortfolioPBLAX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$13,173$2,473.20$11,206$366.19+$2.0KPBLAX
2$17,140$3,044.86$12,650$502.35+$4.5KPBLAX
3$22,043$3,702.61$14,407$694.19+$7.6KPBLAX
4$28,036$4,450.12$16,585$967.82+$11.5KPBLAX
5$35,288$5,289.76$19,342$1,363.89+$15.9KPBLAX
6$43,981$6,222.54$22,913$1,947.19+$21.1KPBLAX
7$54,307$7,248.01$27,662$2,823.89+$26.6KPBLAX
8$66,473$8,364.34$34,159$4,173.35+$32.3KPBLAX
9$80,695$9,568.32$43,337$6,308.80+$37.4KPBLAX
10$97,199$10,855.51$56,776$9,798.13+$40.4KPBLAX

PBLAX vs MRK: Complete Analysis 2026

PBLAXStock

The fund normally invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies with large market capitalizations at the time of purchase that, in the fund's investment advisor's opinion, display characteristics of a "blue chip" company. The advisor tends to focus on securities of companies that show potential for growth of capital as well as an expectation for above average earnings. The fund invests in securities of foreign companies.

Full PBLAX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this PBLAX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PBLAX vs SCHDPBLAX vs JEPIPBLAX vs OPBLAX vs KOPBLAX vs MAINPBLAX vs JNJPBLAX vs ABBVPBLAX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.